Updated hourlyHourly refreshWed, Sep 16, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - BioVaxys Technology Corp. (OTC Pink: BVAXF) (CSE: BIOV) (FSE: 5LB), ("BioVaxys" or the "Company") a clinical-stage biopharmaceutical company focused on the development of durable, single-dose, vaccines for safe, scalable, and long-lasting immune protection in oncology, infectious disease, and immune dysfunctions, is pleased to announce its participation at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences...
Sep 8 · 17:30·mlpr-newsfile
Healthcare · Energy
(PR-inside.com) AUSTIN, TX / ACCESS Newswire / September 8, 2026 / Have you ever felt like your own body is working against you no matter how hard you try to shed stubborn weight? Millions of men and women wake up every day feeling exhausted, struggling with sudden energy crashes right after meals, and fighting relentless late-night cravings that willpower alone just cannot stop. For years, doctors and health experts have pointed to berberine as a breakthrough natural answer for managing blood sugar and kicking metabolism into high gear. However, traditional berberine pills and capsules often come with a heavy price: stomach cramps, ..
Sep 8 · 17:05·PR-Inside
Finance · Healthcare
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SELLAS Life Sciences Group, Inc. ("SELLAS" or "the Company") (NASDAQ:SLS). Investors who purchased SELLAS securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/sellas-life-sciences-group-inc-sls-class_action_lawsuit. SELLAS Investigation Details On August 28, 2026, a news site reported that the Company's phase 3 clinical trial for Galinpepimut-S (GPS) had reached its 80th patient death, a pre-specified event that was to trigger the release of results for the clinical trial. However, as of ..
Sep 8 · 17:05·PR-Inside
Healthcare · Energy
The Canadian astronaut and women's health expert will appear together on stage as a couple, joining Margaret Atwood, Lord David Cameron, Tyler Cowen, and leading voices shaping the future of energy CALGARY, AB, Sept. 8, 2026 /PRNewswire/ -- Energy Disruptors: UNITE has announced Artemis...
Sep 8 · 15:59·PR Newswire
Healthcare · Automotive
Collaboration will explore nutrition as a key driver of cardiovascular health through collaborative research led by Dr. Harold Schmitz AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Humann, the Austin-based cardiovascular health supplement company, continued its legacy of engaging with...
Sep 8 · 15:57·PR Newswire
Healthcare
SALT LAKE CITY, Sept. 8, 2026 /PRNewswire/ -- An extensive, first-of-its-kind research study by ARUP Laboratories clarifies the clinical value of atypical findings from prenatal cell-free DNA (cfDNA) screening and their impact on pregnancy outcomes. The study, which investigated the...
Sep 8 · 15:49·PR Newswire
Healthcare
The article explains how clinical testing can provide detailed information about hearing levels, speech clarity, differences between ears, and everyday listening concerns. LEBANON, Pa., Sept. 8, 2026 /PRNewswire/ -- What can a professional hearing test reveal that an online test cannot? A...
Sep 8 · 15:32·PR Newswire
Finance · Healthcare
(PR-inside.com) NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / September 8, 2026 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for ..
Sep 8 · 15:20·PR-Inside
Finance · AI
(PR-inside.com) Flare Capital Partners leads the round, bringing total funding to $30 million. GenHealth's AI agents complete intake, eligibility, prior authorization, billing, and denials inside the systems providers already use, with customers getting paid 30%+ more. BOSTON, MA / ACCESS Newswire / September 8, 2026 / GenHealth.ai, the healthcare AI company building AI agents that run the medical back office, today announced a $16.5 million Series A led by Flare Capital Partners. Existing investors Craft Ventures and Obvious Ventures participated, along with new investors Eniac Ventures, InHealth Ventures, Epsilon Health Investors, and ARTIS. The round brings GenHealth's total funding to $30 million. The ..
Sep 8 · 15:00·PR-Inside
Finance · Healthcare
Expanded provider relationship increases access to Hoag physicians, hospitals and specialty programs beginning Jan. 1, 2027 Expanded provider relationship increases access to Hoag physicians, hospitals and specialty programs beginning Jan. 1, 2027
Sep 8 · 15:00·GlobeNewswire
Finance · AI
Flare Capital Partners leads the round, bringing total funding to $30 million. GenHealth's AI agents complete intake, eligibility, prior authorization, billing, and denials inside the systems providers already use, with customers getting paid 30%+ more.
Sep 8 · 15:00·Newswire.com
Healthcare
The information contained herein represents a summary of the peer-reviewed journal article published in Thrombosis and Haemostasis entitled "Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors" DANBURY, Conn., Sept. 8, 2026 /PRNewswire/ --...
Sep 8 · 14:58·PR Newswire